HUP0002932A2 - HIV-proteáz inhibitorokat tartalmazó gyógyszerkészítmények - Google Patents

HIV-proteáz inhibitorokat tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0002932A2
HUP0002932A2 HU0002932A HUP0002932A HUP0002932A2 HU P0002932 A2 HUP0002932 A2 HU P0002932A2 HU 0002932 A HU0002932 A HU 0002932A HU P0002932 A HUP0002932 A HU P0002932A HU P0002932 A2 HUP0002932 A2 HU P0002932A2
Authority
HU
Hungary
Prior art keywords
pharmacologically acceptable
hiv protease
function
protease enzyme
inhibit
Prior art date
Application number
HU0002932A
Other languages
English (en)
Inventor
Laman A. Al-Razzak
Rong Gao
Soumojeet Ghosh
Dilip Kaul
John Lipari
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25034589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002932(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HUP0002932A2 publication Critical patent/HUP0002932A2/hu
Publication of HUP0002932A3 publication Critical patent/HUP0002932A3/hu
Publication of HU224319B1 publication Critical patent/HU224319B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Atalálmány olyan cseppfolyós gyógyszerkészítményekre vonatkozik,amelyek orálisan alkalmazva lehetővé teszik a HIV-proteáz enzimműködését gátló inhibitorként ható vegyületek jobb biológiaihasznosulását. Atalálmány szerinti gyógyszerkészítmények olyanoldatok, amelyek a) a HIV-proteáz enzim működését gátló vegyületetvagy a HIV-proteáz enzim működését gátló vegyületek kombinációját; b)farmakológiai szempontból elfogadható, hosszú szénláncú zsírsavbólvagy farmakológiai szempontból elfogadható, hosszú szénláncú zsírsavés farmakológiai szempontból elfogadható alkohol elegyéből álló,farmakológiai szempontból elfogadható szerves oldószert; és adottesetben c) farmakológiai szempontból elfogadható felületaktív anyagottartalmaznak. AHIV-proteáz enzim működését gátló hatóanyagok atalálmány szerinti oldatkészítmény formájában szájon keresztülalkalmazva sokkal jobban hasznosíthatók biológiailag, mint az eddigismert hasonló készítmények. Abiológiai hasznosíthatóság még inkábbnövelhető, ha a találmány szerinti készítményeket kapszulázottformában alkalmazzák. Ó
HU0002932A 1996-11-21 1997-11-12 HIV-proteáz inhibitorokat és 12-18 szénatomos zsírsavakat tartalmazó folyékony gyógyszerkészítmények HU224319B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75439096A 1996-11-21 1996-11-21
PCT/US1997/020794 WO1998022106A1 (en) 1996-11-21 1997-11-12 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
HUP0002932A2 true HUP0002932A2 (hu) 2001-01-29
HUP0002932A3 HUP0002932A3 (en) 2001-03-28
HU224319B1 HU224319B1 (hu) 2005-07-28

Family

ID=25034589

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002932A HU224319B1 (hu) 1996-11-21 1997-11-12 HIV-proteáz inhibitorokat és 12-18 szénatomos zsírsavakat tartalmazó folyékony gyógyszerkészítmények

Country Status (26)

Country Link
EP (2) EP0942721B1 (hu)
JP (2) JP3592337B2 (hu)
KR (2) KR100516567B1 (hu)
CN (3) CN1250219C (hu)
AR (2) AR010634A1 (hu)
AT (1) ATE231393T1 (hu)
AU (1) AU717546B2 (hu)
BG (1) BG64411B1 (hu)
BR (1) BR9714310A (hu)
CA (2) CA2271196C (hu)
CZ (1) CZ299728B6 (hu)
DE (1) DE69718668T2 (hu)
DK (1) DK0942721T3 (hu)
ES (1) ES2191862T3 (hu)
HK (1) HK1053787A1 (hu)
HU (1) HU224319B1 (hu)
IL (1) IL129300A (hu)
NO (1) NO326927B1 (hu)
NZ (1) NZ335002A (hu)
PL (1) PL190185B1 (hu)
PT (1) PT942721E (hu)
SK (1) SK285022B6 (hu)
TR (1) TR199901129T2 (hu)
TW (1) TW475895B (hu)
WO (1) WO1998022106A1 (hu)
ZA (1) ZA9710071B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6121313A (en) * 1997-07-29 2000-09-19 Pharmacia & Upjohn Company Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
KR100509131B1 (ko) * 1997-07-29 2005-08-18 파마시아 앤드 업존 캄파니 엘엘씨 산성 친지성 화합물의, 자가유화 제제 형태의 제약 조성물
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
EP1712231A3 (en) * 1998-11-04 2007-11-21 Pharmacia & Upjohn Company LLC Method for improving the pharmacokinetics of tipranavir
CA2346131C (en) * 1998-11-04 2013-01-15 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DK1183026T3 (da) * 1999-06-04 2006-11-06 Abbott Lab Forbedrede farmaceutiske formuleringer omfattende ritonavir
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE60019334T2 (de) * 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
ES2304990T3 (es) 2000-01-19 2008-11-01 Abbott Laboratories Formulaciones farmaceuticas de inhibidores de la proteasa del vih mejoradas.
WO2001082919A2 (en) * 2000-05-04 2001-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
JP2005508294A (ja) * 2001-05-25 2005-03-31 アボット・ラボラトリーズ リトナビルおよび／またはロピナビルを含む軟弾性カプセル
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
BR0302424A (pt) * 2003-07-23 2005-03-29 Cristalia Prod Quimicos Farm Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
WO2006014282A2 (en) 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
CA2837266A1 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
CN104411300A (zh) 2012-05-03 2015-03-11 希普拉有限公司 抗逆转录病毒组合物
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0558603B1 (en) * 1990-11-19 1998-08-26 Monsanto Company Retroviral protease inhibitors
KR100268694B1 (ko) * 1991-10-11 2000-10-16 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체
SG52731A1 (en) * 1991-11-08 1998-09-28 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ATE141265T1 (de) * 1992-05-20 1996-08-15 Searle & Co Verfahren zur herstellung von intermediaten in der synthese von retroviralen protease inhibitoren
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
PT727419E (pt) * 1992-12-29 2002-08-30 Abbott Lab Compostos intermediarios para a preparacao de inibidores da protease retroviral
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
CZ160299A3 (cs) 1999-08-11
DE69718668T2 (de) 2003-10-02
IL129300A (en) 2003-07-06
AR048891A2 (es) 2006-06-07
BR9714310A (pt) 2000-05-02
IL129300A0 (en) 2000-02-17
AR010634A1 (es) 2000-06-28
TW475895B (en) 2002-02-11
CN1250219C (zh) 2006-04-12
NZ335002A (en) 2001-08-31
CN101103984A (zh) 2008-01-16
KR100516567B1 (ko) 2005-09-22
CN1989963A (zh) 2007-07-04
PT942721E (pt) 2003-06-30
JP2000515555A (ja) 2000-11-21
KR20000057169A (ko) 2000-09-15
HU224319B1 (hu) 2005-07-28
PL336980A1 (en) 2000-07-31
JP4523799B2 (ja) 2010-08-11
KR20040004426A (ko) 2004-01-13
CN1248914A (zh) 2000-03-29
EP1283041A1 (en) 2003-02-12
DK0942721T3 (da) 2003-05-19
AU717546B2 (en) 2000-03-30
HUP0002932A3 (en) 2001-03-28
KR100478075B1 (ko) 2005-03-23
EP0942721B1 (en) 2003-01-22
NO992427L (no) 1999-07-20
CA2271196C (en) 2005-06-28
HK1053787A1 (zh) 2003-11-07
DE69718668D1 (de) 2003-02-27
ZA9710071B (en) 1998-05-25
WO1998022106A1 (en) 1998-05-28
ES2191862T3 (es) 2003-09-16
TR199901129T2 (xx) 2001-05-21
CZ299728B6 (cs) 2008-11-05
BG64411B1 (bg) 2005-01-31
EP0942721A1 (en) 1999-09-22
BG103425A (en) 2000-04-28
ATE231393T1 (de) 2003-02-15
NO992427D0 (no) 1999-05-20
CA2505430A1 (en) 1998-05-28
JP2004346077A (ja) 2004-12-09
SK285022B6 (sk) 2006-04-06
CA2271196A1 (en) 1998-05-28
AU5257398A (en) 1998-06-10
PL190185B1 (pl) 2005-11-30
SK65599A3 (en) 1999-12-10
CN1989963B (zh) 2011-06-29
JP3592337B2 (ja) 2004-11-24
NO326927B1 (no) 2009-03-16

Similar Documents

Publication Publication Date Title
HUP0002932A2 (hu) HIV-proteáz inhibitorokat tartalmazó gyógyszerkészítmények
HUP0201444A2 (hu) Hosszú láncú triglicerideket és lipofil, felületaktív anyagokat tartalmazó orális adagolású gyógyszerkészítmények
FI960012A0 (fi) Vedellinen, monifaasinen, stabiili valmisformulaatti kasvinsuojelussa käytettäviä vaikuttavia aineita varten ja menetelmiä sen valmistamiseksi
UY27320A1 (es) Nuevas composiciones farmacéuticas
DE69418468T2 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
PL335575A1 (en) Hydrophilic two-component systems for use in administration of cyclosporine
GT199900069A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.
MY127749A (en) Liquid formulation
CO5160323A1 (es) Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih
ATE66605T1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
IT1270239B (it) Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
AU2658695A (en) N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors
DE69415018T2 (de) Oralanzuwendende flüssige arzneizubereitung enthaltend 2-(4-isobutylphenyl)propionsäure
IT1272149B (it) Composizione farmeceutiche ad attivita' analgesica
ES2140512T3 (es) Composiciones farmaceuticas que contienen derivados de estaurosporina y un gliceridos polialquilenglicolico.
IT1250672B (it) Formulazioni orali di ubidecarenone in soluzione acquosa
HUP9700842A1 (hu) Hatóanyagok szabályozott felszabadulását biztosító, stabilizált lipofil mátrixalapú gyógyászati készítmények
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
WO2003105826A3 (en) STABLE AND SOLUBLE PHARMACEUTICAL COMPOSITION FOR THE DELIVERY OF HIV PROTEASE INHIBITORS AND METHOD FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE DELIVERY OF HIV PROTEASE INHIBITORS
CO4370014A1 (es) Soluciones inyectables estables de diritromicina
HUP0105210A2 (hu) Moxonidin felhasználása szívizominfraktus utókezelésére
IT1204803B (it) Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
MY116032A (en) Liquid composition comprising an hiv protease inhibitor and a, c12-c18 fatty acid
HUP0204150A2 (hu) A cisz-lítium-4-ciano-4-[3-(ciklopentil-oxi)-4-metoxi-fenil]-ciklohexánkarboxilát monohidrátja, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény
EP1046337A3 (de) Wasserbasierte Formulierungen mit fungizider Wirkung

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050613

GB9A Succession in title

Owner name: ABBVIE INC., US

Free format text: FORMER OWNER(S): ABBOTT LABORATORIES, US